Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;165(3):472-8.
doi: 10.1016/j.jpeds.2014.05.040. Epub 2014 Jul 1.

Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome

Elisha M Wachman  1 , Marie J Hayes  2 , Barry M Lester  3 , Norma Terrin  4 , Mark S Brown  5 , David A Nielsen  6 , Jonathan M Davis  7
Affiliations

Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome

Elisha M Wachman et al. J Pediatr. 2014 Sep.

Abstract

Objective: Neonatal abstinence syndrome (NAS) from in utero opioid exposure is highly variable with genetic factors appearing to play an important role. Epigenetic changes in cytosine:guanine (CpG) dinucleotide methylation can occur after drug exposure and may help to explain NAS variability. We correlated DNA methylation levels in the mu-opioid receptor (OPRM1) promoter in opioid-exposed infants with NAS outcomes.

Study design: DNA samples from cord blood or saliva were analyzed for 86 infants who were being treated for NAS according to institutional protocol. Methylation levels at 16 OPRM1 CpG sites were determined and correlated with NAS outcome measures, including need for treatment, treatment with ≥ 2 medications, and length of hospital stay. We adjusted for covariates and multiple genetic testing.

Results: Sixty-five percent of infants required treatment for NAS, and 24% required ≥ 2 medications. Hypermethylation of the OPRM1 promoter was measured at the -10 CpG in treated vs nontreated infants (adjusted difference δ = 3.2% [95% CI, 0.3-6.0%], P = .03; nonsignificant after multiple testing correction). There was hypermethylation at the -14 (δ = 4.9% [95% CI, 1.8%-8.1%], P = .003), -10 (δ = 5.0% [95% CI, 2.3-7.7%], P = .0005), and +84 (δ = 3.5% [95% CI, 0.6-6.4], P = .02) CpG sites in infants requiring ≥ 2 medications, which remained significant for -14 and -10 after multiple testing correction.

Conclusions: Increased methylation within the OPRM1 promoter is associated with worse NAS outcomes, consistent with gene silencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. OPRM1 Promoter Region
The OPRM1 gene promoter region is shown with the two CpG islands boxed in and CpG dinucleotides indicated as ∣. The major transcription start site is indicated by the arrow, located −253 upstream of the ATG translation start site. The sequence of the amplified CpG island is also shown with the 16 CpG sites analyzed for cytosine methylation (bold) and their position relative to the ATG translation start site (underlined) indicated. Three putative Sp1 transcription factor binding sites are boxed.
Figure 2
Figure 2
Percent methylation of 16 CpG sites within the OPRM1 promoter in opioid-exposed infants who were treated (n=65) versus non-treated (n=21) for NAS. CpG sites in Sp1 transcription factor binding sites are indicated. * p<0.05 in bivariable analyses.
Figure 3
Figure 3
Percent methylation of 16 CpG sites within the OPRM1 promoter in opioid-exposed infants treated with ≥2 medications (n=21) versus <2 medications (n=65) for NAS. CpG sites in Sp1 transcription factor binding sites are indicated. * p<0.05 in bivariable analyses.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000 – 2009. JAMA. 2012;307:1934–40. - PubMed
    1. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Administration. Results from the 2011 National Survey on Drug Use and Health: National Findings. 2011.
    1. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540–60. - PubMed
    1. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009;5:47–55. - PMC - PubMed
    1. Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, Stine SM, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012;107 (Suppl 1):45–52. - PMC - PubMed

Publication types